• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AnaptysBio Inc. (Amendment)

    2/14/24 10:01:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    SC 13G/A 1 p24-0803sc13ga.htm ANAPTYSBIO, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Anaptysbio, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    032724106

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 03272410613G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    788,545

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    788,545

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    788,545

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 03272410613G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    788,545

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    788,545

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    788,545

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 03272410613G/APage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    788,545

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    788,545

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    788,545

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 03272410613G/APage 5 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
      Anaptysbio, Inc. (the “Issuer”).
    Item 1(b). Address of Issuer's Principal Executive Offices.
      10770 Wateridge Circle, Suite 210, San Diego, CA 92121.

     

    Item 2(a). Name of Person Filing.
     

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.001 per share (“Shares”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.001 per share.

     

    Item 2(e). CUSIP Number.
      032724106

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2023.

     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

     

    CUSIP No. 03272410613G/APage 6 of 7 Pages

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      See Item 2(a).
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
      Not applicable.

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 03272410613G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
     

    Title: Authorized Person

     

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

     
    STEVEN A. COHEN
     
    By:  /s/ Jason M. Colombo
    Name:  Jason M. Colombo
    Title:    Authorized Person
     

     

    Get the next $ANAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    4/16/2024$47.00Outperform
    Leerink Partners
    4/11/2024$56.00Overweight
    Wells Fargo
    3/12/2024$20.00 → $34.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $ANAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on AnaptysBio with a new price target

      Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00

      2/4/25 6:58:43 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded AnaptysBio from Buy to Neutral and set a new price target of $19.00 from $52.00 previously

      12/11/24 12:23:14 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by BTIG Research

      BTIG Research downgraded AnaptysBio from Buy to Neutral

      12/2/24 6:53:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    SEC Filings

    See more
    • SEC Form 10-Q filed by AnaptysBio Inc.

      10-Q - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:19:46 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:17:51 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.

      SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      4/30/25 10:57:53 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schmid John P. acquired $201,241 worth of shares (11,068 units at $18.18) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      3/27/25 4:10:12 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. exercised 42,337 shares at a strike of $6.50, increasing direct ownership by 1,086% to 46,237 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/15/25 5:04:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Lizzul Paul F. covered exercise/tax liability with 6,597 shares and converted options into 16,700 shares, increasing direct ownership by 65% to 25,643 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/7/25 5:33:21 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

      Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of JuneInitial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulatorAuthorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027 SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, tod

      5/5/25 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Anaptys Announces Stock Repurchase Plan

      SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Notwithstanding the potential full execution of the Stock Repurchase Plan, the Company reiterates its previ

      3/24/25 9:15:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 4:00:05 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 9:24:47 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

      SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

      8/16/24 12:07:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

      After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a

      9/18/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/2/25 6:17:02 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      8/16/24 12:04:31 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Financials

    Live finance-specific insights

    See more
    • AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

      Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b

      5/11/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care